Medicare Investigation Reveals a Sharp Rise in Controversial and Expensive Prostate Cancer Treatment - WSJ.com

Links shared publicly online about this topic.

671
total visits

Medicare Investigation Reveals a Sharp Rise in Controversial and Expensive Prostate Cancer Treatment - WSJ.com

Roughly one in three Medicare beneficiaries diagnosed with prostate cancer today gets a sophisticated form of radiation therapy called IMRT. Eight years ago, virtually none did. The story behind the sharp rise of IMRT is about more than the rapid adoption of a new technology. It's also about financial incentives, a Wall Street Journal investigation of Medicare data shows.

View full resource at online.wsj.com

Tags: Cancer, Prostate Cancer, Prostate, Men's Health, Health Insurance, Medicare, Oncology, Radiation